We find that high expression of ATAD2 predicts poor outcome and significantly associates with markers for aggressive endometrial cancer, such as high FIGO stage and high grade, non-endometrioid type, and loss of hormone receptors AR, PR and ERα. Here, NR4A1 is linked to endometrial cancer.